Anakinra and Intravenous IgG versus Tocilizumab in the Treatment of COVID-19 Pneumonia

Massa Zantah, MD¹, Eduardo Dominguez Castillo, MD¹, Andrew J. Gangemi, MD¹, Maulin Patel, MD¹, Junad Chowdhury, MD¹, Steven Verga, MD¹, Osheen Abramian, MD¹, Matthew Zheng, MD¹, Kevin Lu, MD², Arthur Lau, MD², Justin Levinson MD², Hauquing Zhao, PhD, MS³, Gerard J.Criner, MD¹, Roberto Caricchio, MD² for the Temple University COVID-19 Research Group⁴

Departments of Rheumatology¹, Thoracic Medicine and Surgery² and Biostatistics³ at the Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140

⁴Temple University COVID-19 Research Group (names in supplementary file).

Correspondence and reprint requests:

Massa Zantah, MD

Department of Thoracic Medicine and Surgery

745 Parkinson Pavilion

Temple University Hospital

3401 North Broad Street

Philadelphia PA 19140

Email: massa.zantah@tuhs.temple.edu

Phone: 267-788-3828

Fax: 215-707-6867

Keywords: COVID-19, Anakinra, Tocilizumab, cytokine storm

Abstract word count: 308

Main text word count: 2778

Table count: 6

Figure count: 2

Abstract:

Background: COVID-19 can lead to acute respiratory failure and an exaggerated inflammatory response. Studies have suggested promising outcomes using monoclonal antibodies targeting IL-1β (Anakinra) or IL6 (Tocilizumab), however no head to head comparison was done between the two treatments. Herein, we report our experience in treating COVID-19 pneumonia associated with cytokine storm with either subcutaneous Anakinra given concomitantly with intravenous immunoglobulin (IVIG), or intravenous Tocilizumab.

Methods: Comprehensive clinical and laboratory data from patients with COVID-19 pneumonia admitted at our hospital between March and May 2020 were collected. Patients who received either Anakinra/ IVIG or Tocilizumab were selected. Baseline characteristics including oxygen therapy, respiratory status evaluation using ROX index, clinical assessment using NEWS score and laboratory data were collected. Outcomes included mortality, intubation, ICU admission and length of stay. In addition, we compared the change in ROX index, NEWS score and inflammatory markers at days 7 and 14 post initiation of therapy.

Results: 84 consecutive patients who received either treatment (51 in the Anakinra/ IVIG group and 33 in the Tocilizumab group) were retrospectively studied. Baseline inflammatory markers were similar in both groups. There was no significant difference regarding to death (21.6% vs 15.2%, p 0.464), intubation (15.7% vs 24.2%, p 0.329), ICU need (57.1% vs 48.5%, p 0.475) or length of stay (13±9.6 vs 14.9±11.6, p 0.512) in the Anakinra/IVIG and Tocilizumab, respectively. Additionally, the rate of improvement in ROX index, NEWS score and inflammatory markers was similar in both groups at days 7 and 14. Furthermore, there was no difference in the incidence of superinfection in both groups.

Conclusion: Treating COVID-19 pneumonia associated with cytokine storm features with either subcutaneous Anakinra/IVIG or intravenous Tocilizumab is associated with improved clinical outcomes in most subjects. The choice of treatment does not appear to affect morbidity or mortality. Randomized controlled trials are needed to confirm our study findings.

Funding: None.

Introduction:

Since the first case was reported in December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has resulted in over 10 million □ confirmed infections and over 500,000 deaths worldwide. The number of cases continues to rise in many countries, including in the US. The disease has overwhelmed the health care systems globally and nationally. Thus far, no effective therapy has been proven to treat COVID-19 disease. Available therapies include supportive care, antibiotics and invasive and noninvasive oxygen support. In addition, off-label therapies including antiretrovirals, antiparasitic agents, anti-inflammatory medications, and convalescent plasma have been used. 3-8

In its severe form, the virus can lead to a life-threatening pneumonia and acute respiratory distress syndrome (ARDS). Although the mechanisms of COVID-19- induced lung injury are still being examined, cytokine storm has been thought to play a role in disease pathophysiology. This form of hyperactive and dysregulated immune response may lead to hyperinflammatory form of ARDS, extrapulmonary multiple-organ failure, and is associated with critical illness and increased mortality. 9-¹¹ Cytokine storm-related respiratory failure carries significant morbidity; in a large retrospective review of hemophagocytic lymphohistiocytosis (HLH), a form of "cytokine storm syndromes," 66% of patients required advanced mechanical ventilatory support, with 40-50% requiring additional vasopressor and renal replacement therapy; mortality approached 53%. ¹² Some of the proposed treatments for COVID-19 pneumonia aim to target the aforementioned inflammatory cascade, monoclonal antibodies targeting interleukins (e.g. Sarilumab, Anakinra, and Tocilizumab) are still under investigation in large randomized clinical trials (NCT04322773, NCT04315298) however evidence from retrospective, observational studies and case reports suggest the effectiveness of some of these therapies. Herein, we present our experience in the treatment of COVID-19 disease, in which we used both recombinant IL-1 receptor antagonist and IL6 monoclonal antibody targeting agents and compared them in our population of COVID 19 patients with moderate to severe hypoxemic repsiroatry failure due to pneumonia. These therapies were given in addition to a corticosteroid, which has been recently found to significantly reduce mortality in patients with COVID-19 on respiratory support.⁶ Furthermore, we present an approach using intravenous immunoglobulin (IVIG) in conjunction with subcutaneous anakinra. The combination of IVIG, anakinra, and corticosteroids has been used with success in treating the immune dysregulation associated with secondary HLH and macrophage activation syndrome. 13-15

Material and Methods:

Study Design and Population:

This is a single center retrospective review conducted at Temple University Hospital. We included consecutive patients admitted between March 17th and May 7th, 2020 and treated for COVID-19 viral pneumonia. The diagnosis of COVID-19 pneumonia was based on a constellation of clinical, radiographic and laboratory findings. Clinical criteria include signs or symptoms of COVID-19 disease such as fever, cough or shortness of breath. All patients had computed tomography (CT) of the chest on admission to detect and quantitate the extent of pulmonary infiltrate. The presence of bilateral peripheral ground-glass opacities (GGOs) was considered highly suggestive of COVID-19 pneumonia. Laboratory findings that help make the diagnosis include positive nasopharyngeal polymerase chain reaction (PCR) for SARS-CoV-2 and/or lymphopenia, elevated inflammatory markers including C-reactive protein (CRP), lactate dehydrogenase (LDH), Ferritin, and D dimer. Patients who received Anakinra with intravenous immunoglobulin (IVIG), or Tocilizumab were included in the study. *Study Treatments:*

The decision for the treatment was made after a multidisciplinary discussion that involved pulmonary and rheumatology specialists. ¹⁶ A consensus was based on: 1) worsening respiratory status defined as increased oxygen supplementation required to maintain SpO₂≥ 93%, and 2) elevation above 3-fold the upper normal level of at least two of the following markers: CRP, ferritin, D-dimer, LDH and cardiac troponin. Patients meeting the above criteria were treated with either therapy unless contraindicated. Anakinra was given subcutaneously at a dose of 100mg every 6 hours or 100mg every 12 hours for renal impairment for 7 days; along with IVIG 0.5g/kg/day for 3 days. Tocilizumab was given intravenously and dosed 8 mg/kg in a single infusion and repeated within 12 hrs if conditions worsened or at 24 hrs if no clinical improvement.

Data Collection and Measures:

All the data were collected using our electronic medical records. Demographics included age, gender, ethnicity, and body mass index (BMI).

Comorbidities including hypertension (HTN) diabetes (DM), coronary artery disease (CAD), congestive heart failure (CHF), chronic kidney disease (CKD), dialysis-dependent end-stage renal disease (ESRD), human immunodeficiency status (HIV), and history of malignancy were gathered for all patients.

Baseline laboratory data included inflammatory markers (CRP, LDH, Ferritin, D dimer, Fibrinogen, Triglyceride), absolute lymphocyte count, Albumin, kidney function measured by blood urea nitrogen/creatinine (BUN/Cr) ratio, liver function testing; Alanine transaminase and Aspartate transaminase (ALT and AST).

Respiratory function status was evaluated using the ROX index. This is defined as the ratio of oxygen saturation as measured by pulse oximetry/FIO2 to respiratory rate. ROX index has been assessed as a predictor of high-flow nasal cannula treatment and need for intubation. Higher scores (ROX \geq 4.88) predict low risk for intubation.

Clinical assessment for patients was detected using the National Early Warning Scores 2 (NEWS2). The NEWS2 score was developed by the Royal College of Physicians and modified for use with hypoxic and hypercapnic respiratory failure; it was also validated in a small study of COVID-19 patients. It takes into account six physiological findings and one observation (respiratory rate, oxygen saturation, supplemental oxygen status, temperature, systolic blood pressure, heart rate and level of consciousness). A score of ≥ 5 signifies a need for ICU monitoring. ^{17,18}

Clinical Outcomes:

Our co-primary endpoints were death and need for intubation. Secondary outcomes included the need for an intensive care unit (ICU), hospital length of stay (LOS), changes in ROX index, NEWS2 score, and laboratory data at day 7 and 14 from initiation of treatment. Additionally, we reported secondary infections (bacteremia and/or ventilator associated pneumonia) in both groups.

Data Analysis:

Data are presented as means with standard deviations (SD) for continuous variables or as percentages for categorical variables. We used a chi-squared test for categorical data, and a two-sided t-test for continuous data. P values < 0.05 were considered statistically significant. The Fisher exact test was used for simple between-group comparisons. Survival data was presented on Kaplan Meier curve. The software we used to run the statistics was Stata 14 (*Stata Statistical Software: Release 14*. College Station, TX: StataCorp LP). A univariate subanalysis was performed to compare the results between dead and survivors of the study population. The Temple University Hospital Institutional Review Board approved the protocol.

5

Results:

Baseline characteristics:

A total of 51 patients who were treated with subcutaneous Anakinra and IVIG and 33 patients who received intravenous Tocilizumab were identified for the study. Their baseline characteristics including demographics and comorbidities are listed in Table-1. The majority of patients in both groups were males (63.1%), with a mean age of 60.6±13.4 years. Mean BMI was 31.4±8.0 kg/m². The diagnosis of the majority of patient was made using nasopharyngeal swab for Cov2-SAR PCR (77.4%). There was no significant difference in regard to comorbidities in both groups, including COPD, asthma, DM, HTN, CAD, CHF, CKD and ESRD. Unless contraindicated, all patients requiring oxygen therapy received Corticosteroids, with a mean dose (methylprednisolone equivalent) of 218.1±149.7 mg in the Anakinra/IVIG versus 246.2±129.8 mg in the Tocilizumab group, p= 0.37. In both groups, patients had similarly elevated baseline inflammatory markers including CRP (8.5±5.9 versus 9.4±8.6 mg/L), LDH (508.1±575.6 versus 345.1±106.4 U/L), D dimer (6126.1±17554.9 versus 1398.4±2798.8 ng/mL), fibrinogen (508.5±117.8 versus 537.6±138.2 mg/dL), and triglycerides (137.4±82.6 versus 146.5±96.8 mg/dL), in the Anakinra/ IVIG and Tocilizumab respectively (Table-2).

In regard to clinical assessment, patients in the Tocilizumab group had worse baseline respiratory function and NEWS score. ROX index was 13.6±7.6 versus 8.4±6.3, p 0.002 and NEWS score was 5.6±3.5 versus 7.5±3.5, p 0.017 in the Anakinra/ IVIG compared to Tocilizumab. The majority of patients in both groups were on low-flow nasal cannula, however, although not statistically significant, more patients in the Tocilizumab group required high-flow nasal cannula (33.3% versus 17.6%) and invasive mechanical ventilation (24.2% versus 15.7%, p=0.191) compared to the Anakinra/IVIG group (Table-2).

Clinical Outcomes:

There was no significant difference in mortality among patients who received Anakinra/IVIG or Tocilizumab (21.6% versus 15.2%, p 0.464. Figure-1). Furthermore, there was no significant difference in regard to other clinical outcomes including intubation (15.7% versus 24.2%, p 0.329), need for ICU (57.1% versus 48.5%, p=0.475), length of stay (13.4±9.6 versus 14.9±11.6, p=0.512) for Anakinra/IVIG compared to Tocilizumab respectively. Although sicker at baseline, patients in the Tocilizumab group when compared to patients in the Anakinra/IVIG had the same rate of improvement in clinical parameters including change in ROX index from baseline at day 7 (6.6±6.5 versus 4.9±6.6, p 0.257) and day 14 (7.8±4.8 versus 6.5±5.8, p 0.537). Similar results were noted regarding change in NEWS score at day 7 (-2.1±3.7 versus -2.2±3.1, p 0.962) and day 14 (-2.2±4.0

versus -2.2±2.0, p 0.989) in the Tocilizumab versus Anakinra/IVIG. We found similar rates of secondary infections (17.6% versus 24.2%, p 0.462) in both groups (Table-3).

A univariate analysis was then done to compare baseline characteristics and outcomes among living and deceased patients in both groups. The analysis revealed that patients who died were older (57.8 +12.7 years versus 72.8+ 8.7 years, p<0.0001) and had more cardiac and renal comorbidities (Table-4). Additionally, patients who died had more severe disease at baseline indicated by significantly worse ROX index and NEWS scores and increased need for invasive mechanical ventilation (Table-5). Clinical Outcomes for patients in both groups are summarized in Table-6. Changes in each inflammatory marker post treatment initiation in both groups are represented in Figure-2. Interestingly, the amelioration of inflammatory markers such as CRP, fibrinogen and stabilization of lymphopenia were similar among the groups. However, compared to those who survived, patients who died had a significant worsening in their inflammatory markers (Figure-2).

Discussion:

To our knowledge, this is the first study that compares two unique treatments for COVID-19 pneumonia in patients with hyperinflammatory response. Although their mechanisms are different, the desired outcomes appear to be somewhat similar. As noted, at baseline, both patient populations are comparable in terms of demographics and comorbidities. They also have similar inflammatory responses indicated by elevated levels of CRP, LDH, Fibrinogen and D-dimers in both groups. However, patients who received Tocilizumab were sicker in regard to their clinical data (lower baseline ROX index and higher NEWS score). To some extent, this reflects a selection bias as intravenous biologic treatment was preferred over subcutaneous therapies to avoid delay in treatment response in rapidly deteriorating patients. Subcutaneous injections can have variable absorption characteristics, particularly with factors such as obesity and anasarca that can extend the half-life, and do not achieve the maximum serum concentrations possible with intravenous administration. These issues led us to add intravenous IgG to the anakinra regimen so that a concomitant faster treatment could be provided. Nevertheless, the outcomes were similar in both groups in regard to mortality, intubation, ICU admission, length of stay and improvement in inflammatory markers. There was also no significant difference in the rate of secondary infection in both groups.

Based on our results, it appears that regardless of the advanced therapy given (Anakinra/IVIG or Tocilizumab), patients who are older, who have cardiac or renal comorbidities, and show more disease burden and organ dysfunction (indicated by ROX index and NEWS scores) are at highest risk for mortality. Another important finding in our study is that response to therapy at 7- and 14-days may predict overall outcomes for the patient. Baseline inflammatory markers did not differentiate those who died from the ones who survived; however, failure of those markers to improve after therapy appears to have important prognostic value. Indeed, ferritin levels that fail to decline in classical HLH also correlate with worse outcomes.¹⁵

Given the retrospective design, it may be challenging to make a comparison and draw conclusions between our study, and the studies that have been published recently in the literature. However, we believe that our results are fairly similar in regard to mortality and safety outcomes. In studies that evaluated Anakinra as a treatment for COVID-19 pneumonia, mortality ranged anywhere between 10 to 25%, (21.6% in our population). Improvement in clinical outcomes was also noted in several retrospective, observational studies, case series and case reports. These outcomes include ICU admission, improvement in inflammatory markers, radiographic findings and respiratory parameters. 14,19-25

It is important to mention that Anakinra was used subcutaneously in many of the aforementioned studies, and the dose used was smaller than the one we considered in our practice. ^{19,22-25} We argue that this should take into account the onset of action of the medication, and thus perhaps higher doses of Anakinra to achieve the desired rapid effectiveness are required, especially in treating critically ill patients. This may not be the case of concern when using intravenous Anakinra, however this form may not be widely available. In fact, in a study by Cavalli et al. high dose intravenous Anakinra achieved better outcomes compared to lower dose treatment or standard of care. In the same study, low dose subcutaneous Anakinra was initially used but the treatment was stopped due to paucity of effect after 7 days. Similarly, a case series by Millan et al. revealed that patients who benefitted from receiving subcutaneous Anakinra were those who received it early in the course of disease (≤36 hours). In our study, we chose to give a high dose of subcutaneous Anakinra given lack of availability of the intravenous form; in addition, we used IVIG concomitantly in the first three days to augment the action of Anakinra, similar to other cytokine storm protocols. ¹³⁻¹⁵

Our data on treating COVID-19 patients with tocilizumab are similar to those treated with Anakinra favoring this advanced therapy, and mostly align with the limited retrospective reports and case series

that have been published thus far. Mortality ranged between 16 to 52% (15.2% in our study) with higher mortality observed in older, sicker patients, severe ARDS and especially in those who were on invasive mechanical ventilation. Secondary infection, which may be a concern when using IL-1 or IL-6 blockers were not significantly different between the two therapies. Our results on superinfection are similar to what have been reported in the literature, 12 to 14% with higher rates of superinfections observed in mechanically ventilated and ICU patients. Likewise, the limited HLH literature does not suggest a substantially increased risk of bacterial superinfection despite combination anti-inflammatory therapy, with anakinra potentially less myelotoxic than anti-interleukin 6 therapy. All the standard potentially less myelotoxic than anti-interleukin 6 therapy.

Interestingly, despite having two different mechanisms, both treatments resulted in a similar rate of improvement in clinical data and inflammatory markers. This suggests a common pathway of these two approaches that results in amelioration of inflammation parameters and eventually controlling the storm. This is extremely important in patients with severe respiratory failure, which may correlate to the decrease in CD4 and NK cells, the reduction in cytotoxic potentials, and the increase in proinflammatory cytokines levels, such as IL-1, IL-6, tumor necrosis factor alpha, and interferon gamma. In these patients Tocilizumab has been shown to restore IL-6 mediated response of CD4 and NK cells and increase the number of circulating lymphocytes. 10,12,33 Anakinra instead reduces circulating levels of the IL-1 β and is thought to help in halting the inflammatory cascade caused by SARS-CoV2 virus.

Corticosteroids are added to also blunt the inflammatory response. At our institution, we initiated corticosteroids in patients with moderate-severe disease burden based on experience from colleagues in China.³⁴ One study has suggested that adding methylprednisolone to Tocilizumab decreases the risk of death.³⁵ Results of randomized data from >6000 patients in the United Kingdom suggest a mortality benefit with the use of dexamethasone.⁷

The main limitation of our study is due to its retrospective, single center observational design. This design may put our study at risk for possible selection bias given no randomization to treatment or standard of care arm. Furthermore, patients were selected for each therapy depending on drug availability in our institution. The fact that we found equivalent outcomes between the two groups does provide encouragement in this regard, as real-world situations may limit the choice of drug

availability at different institutions. The ubiquitous use of steroids at our institution might present a confounding factor, however anti-interleukin therapy was often added after failure of corticosteroid treatment.

Conclusion:

In summary, our study suggests that treating COVID-19 pneumonia associated with cytokine storm features with either subcutaneous Anakinra/IVIG or intravenous Tocilizumab is associated with improved clinical outcomes in most subjects. The choice of therapy does not seem to affect morbidity or mortality. We believe that the addition of IVIG may offset the less efficacious use of subcutaneous anakinra, especially in centers where the intravenous form is not available. Our data provide meaningful information to clinicians that care for patients with COVID-19 disease. Randomized, prospective clinical trials are needed to confirm our study findings.

References:

- 1. Organization, W. H. Novel coronavirus—China. https://www.who.int/csr/don/12-january-2020-novel-coronavirus-chinaExternal Link (2020).
- 2. Organization, W. H. Coronavirus disease (COVID-19) Situation Report 163. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200701-covid-19-sitrep-163.pdf?sfvrsn=c202f05b_2 (2020).
- 3. Agarwal, A. *et al.* High-flow nasal cannula for acute hypoxemic respiratory failure in patients with COVID-19: systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission. *Can J Anaesth J Can D'anesthesie* 1–32 (2020) doi:10.1007/s12630-020-01740-2.
- 4. Grein, J. *et al.* Compassionate Use of Remdesivir for Patients with Severe Covid-19. *New Engl J Medicine* **382**, 2327–2336 (2020).
- 5. Geleris, J. *et al.* Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. *New Engl J Medicine* **382**, 2411–2418 (2020).
- 6. Group, R. C. *et al.* Dexamethasone in Hospitalized Patients with Covid-19 Preliminary Report. *New Engl J Medicine* (2020) doi:10.1056/nejmoa2021436.

- 7. Horby, P. et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. *Medrxiv* 2020.06.22.20137273 (2020) doi:10.1101/2020.06.22.20137273.
- 8. Bloch, E. M. *et al.* Deployment of convalescent plasma for the prevention and treatment of COVID-19. *J Clin Investigation* **130**, 2757–2765 (2020).
- 9. Qin, C. *et al.* Dysregulation of immune response in patients with COVID-19 in Wuhan, China. *Clin Infect Dis Official Publ Infect Dis Soc Am* (2020) doi:10.1093/cid/ciaa248.
- 10. Giamarellos-Bourboulis, E. J. *et al.* Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. *Cell Host Microbe* **27**, 992-1000.e3 (2020).
- 11. Ye, Q., Wang, B. & Mao, J. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19. *J Infect* **80**, 607–613 (2020).
- 12. Seguin, A., Galicier, L., Boutboul, D., Lemiale, V. & Azoulay, E. Pulmonary Involvement in Patients With Hemophagocytic Lymphohistiocytosis. *Chest* **149**, 1294–301 (2016).
- 13. Wohlfarth, P. *et al.* Interleukin 1 Receptor Antagonist Anakinra, Intravenous Immunoglobulin, and Corticosteroids in the Management of Critically Ill Adult Patients With Hemophagocytic Lymphohistiocytosis. *J Intensive Care Med* **34**, 723–731 (2017).
- 14. Dimopoulos, G. *et al.* Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis. *Cell Host Microbe* (2020) doi:10.1016/j.chom.2020.05.007.
- 15. Mehta, P., Cron, R. Q., Hartwell, J., Manson, J. J. & Tattersall, R. S. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. *Lancet Rheumatology* **2**, e358–e367 (2020).
- 16. Caricchio, R. & Criner, G. J. Rheumatologists and Pulmonologists at Temple University weather the COVID-19 storm together. *J Rheumatology* jrheum.200740 (2020) doi:10.3899/jrheum.200740.
- 17. Gidari, A., Socio, G. V. D., Sabbatini, S. & Francisci, D. Predictive value of National Early Warning Score 2 (NEWS2) for intensive care unit admission in patients with SARS-CoV-2 infection. *Infect Dis-nor* 1–7 (2020) doi:10.1080/23744235.2020.1784457.
- 18. Williams, B. The National Early Warning Score 2 (NEWS2) in patients with hypercapnic respiratory failure. *Clin Med* **19**, 94–95 (2019).
- 19. Huet, T. et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatology 2, e393–e400 (2020).
- 20. Cavalli, G. *et al.* Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. *Lancet Rheumatology* **2**, e325–e331 (2020).
- 21. Pontali, E. *et al.* Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease. *J Allergy Clin Immun* **146**, 213–215 (2020).

- 22. Franzetti, M. *et al.* Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report. *Int J Infect Dis* (2020) doi:10.1016/j.ijid.2020.05.050.
- 23. González-García, A. *et al.* Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment. *Rheumatology* keaa318- (2020) doi:10.1093/rheumatology/keaa318.
- 24. Aouba, A. *et al.* Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series. *Ann Rheum Dis* annrheumdis-2020-217706 (2020) doi:10.1136/annrheumdis-2020-217706.
- 25. Navarro ☐ Millán, I. *et al.* Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID ☐ 19: A Case Series. *Arthritis Rheumatol* (2020) doi:10.1002/art.41422.
- 26. Rojas-Marte, G. *et al.* Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case–controlled study. *Qjm Int J Medicine* hcaa206- (2020) doi:10.1093/qjmed/hcaa206.
- 27. Toniati, P. *et al.* Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. *Autoimmun Rev* **19**, 102568 (2020).
- 28. Somers, E. C. *et al.* Tocilizumab for treatment of mechanically ventilated patients with COVID-19. *Medrxiv* 2020.05.29.20117358 (2020) doi:10.1101/2020.05.29.20117358.
- 29. Morena, V. *et al.* Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy. *Eur J Intern Med* (2020) doi:10.1016/j.ejim.2020.05.011.
- 30. Campochiaro, C. *et al.* Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. *Eur J Intern Med* (2020) doi:10.1016/j.ejim.2020.05.021.
- 31. Antwi ☐ Amoabeng, D. *et al.* Clinical outcomes in COVID ☐ 19 patients treated with tocilizumab: An individual patient data systematic review. *J Med Virol* (2020) doi:10.1002/jmv.26038.
- 32. Xu, X. *et al.* Effective treatment of severe COVID-19 patients with tocilizumab. *Proc National Acad Sci* **117**, 10970–10975 (2020).
- 33. Mazzoni, A. *et al.* Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. *J Clin Invest* (2020) doi:10.1172/jci138554.
- 34. Commission, C. N. H. Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th edition). (2020).
- 35. Herrero, F. S. *et al.* Methylprednisolone added to tocilizumab reduces mortality in SARS \square CoV \square 2 pneumonia: An observational study. *J Intern Med* (2020) doi:10.1111/joim.13145.

Table 1- Baseline Characteristics:

Demographics	Total	Anakinra/IVIG	Tocilizumab	P-value
	n=84	n=51	n=33	
Gender (%)				0.704
Male	53 (63.1)	33 (64.7)	20 (60.6)	
Female	31 (36.9)	18 (35.3)	13 (39.4)	
Mean Age, years	60.6±13.4	62.7±12.3	57.4±14.6	0.074
Ethnicity (%)				0.660
AA	45 (53.6)	28 (54.9)	17 (51.5)	
Hispanic	25 (29.8)	15 (29.4)	10 (30.3)	
Caucasian	13 (15.5)	8 (15.7)	5 (15.2)	
Not known /NON	1 (1.2)	0 (0.0)	1 (3.0)	
Hispanic				
Mean BMI (kg/m²)	31.4±8.0	30.0±7.7	33.7±8.1	0.035
COVID PCR	65 (77.4)	41 (80.4)	24 (72.7)	0.412
positive status (%)				
	Co	morbidities		
COPD (%)	23 (27.4)	17 (33.3)	6 (18.2)	0.128
Asthma (%)	8 (9.5)	4 (7.8)	4 (12.1)	0.514
HTN (%)	60 (71.4)	37 (72.5)	23 (69.7)	0.777
DM (%)	36 (42.9)	18 (35.3)	18 (35.3)	0.082

CAD (%)	16 (19.0)	11 (21.6)	5 (15.2)	0.464
CHF (%)	17 (20.2)	8 (15.7)	9 (27.3)	0.197
CKD (%)	12 (14.3)	8 (15.7)	4 (12.1)	0.648
ESRD on dialysis (%)	11 (13.1)	8 (15.7)	4 (9.1)	0.382
Malignancy (%)	4 (4.8)	4 (7.8)	0 (0.0)	0.099
HIV (%)	4 (4.8)	1 (2.0)	3 (9.1)	0.134
Highest Corticosteroid dose (Methylprednisolo ne) (mg)	229.1±142.1	218.1±149.7	246.2±129.8	0.379

Table-2 Baseline Laboratory, Respiratory Function and Clinical Data

	Total n=84	Anakinra/IVIG n=51	Tocilizumab n=33	P value
	Baseline laborate	ory Inflammatory M	arkers	
CRP (mg/L)	8.9±7.0	8.5±5.9	9.4±8.6	0.622
Ferritin (ng/mL)				0.081
Mean	1599.2±5084.2	2276.8±6413.5	520.2±434.2	
Median (IQR)	563.5 (247.0-993.0)	628.0 (360.0-	348.0 (175.0-	
		1090.0)	878.0)	
LDH (U/L)	446.4±463.4	508.1±575.6	345.1±106.4	0.068
AST (U/L)				0.153
Mean	116.8±386.5	156.8±484.8	51.2±71.1	
Median (IQR)	37.5 (25.0-66.0)	39.0 (24.0-80.0)	36.0 (30.0-47.5)	
ALT (U/L)				0.461
Mean	97.1±25.5	111.7±297.0	73.2±147.5	
Median (IQR)	43.0 (22.0-69.0)	41.0 (22.0-74.0)	43.0 (21.5-59.5)	
Albumin (g/dL)	2.6±0.4	2.5±0.4	2.6±0.4	0.655
D-dimer (ng/mL)				0.087
Mean	4328.3±14055.6	6126.1±17554.9	1398.4±2798.8	
Median (IQR)	843.0 (521.0-	1073.5 (606.5-	789.0 (387.0-	
	1745.0)	2669.5)	909.0)	
Fibrinogen (mg/dL)	519.3±163.7	508.5±177.8	537.6±138.2	0.485
Triglycerides	141±87.8	137.4±82.6	146.5±96.8	0.691

(mg/dL)				
(mg/uL)				
Absolute	0.9 ± 0.6	0.9±0.6	0.9±0.6	0.838
Lymphocyte				
Count (K/mm ³)				
BUN/Creatinine	23.9±12.4	23.9±13.4	23.9±10.8	0.989
ratio				
	Respi	ratory Function		
Mean ROX index	11.6±7.5	13.6±7.6	8.4±6.3	0.002
at day 0				
Maximum				0.191
Oxygen Support				
None (%)	6 (7.1)	5 (9.8)	1 (3.0)	
NC (%)	38 (45.2)	27 (52.9)	11 (33.3)	
HFNT (%)	20 (23.8)	9 (17.6)	11 (33.3)	
NIPPV (%)	3 (3.6)	2 (3.9)	1 (3.0)	
IMV (%)	16 (19.0)	8 (15.7)	8 (24.2)	
ECMO (%)	1 (1.2)	0 (0.0)	1 (3.0)	
Clinical Data				
NEWS score on	6.3±3.6	5.6±3.5	7.5±3.5	0.017
day 0				

^{*}NC- Nasal cannula, HFNT- High flow nasal Therapy, NIPPV- Non-invasive Positive Pressure

Ventilation, IMV - invasive mechanical Ventilation, ECMO- Extracorporeal Membrane oxygenation,

NEWS - National early warning Score

Table-3 Clinical Outcomes

5 (15.2) 8 (24.2) 16 (48.5)	0.464 0.329 0.475
16 (48.5)	0.475
, ,	
	0.252
17 (51.5)	0.352
14.9±11.6	0.512
9.5±9.3	0.474
)	

				1
Duration of Invasive Mechanical of Ventilation (days)	13.3±10.9	12.9±13.2	13.6±9.6	0.904
Change in NEWS score from baseline at day 7	-2.1±3.3	-2.2±3.1	-2.1±3.7	0.962
Change in NEWS score from baseline day 14	-2.2±3.2	-2.2±2.0	-2.2±4.0	0.989
Change in ROX index from baseline at day 7	5.6±6.6	4.9±6.6	6.6±6.5	0.257
Change in ROX index from baseline at Day	7.2±5.3	6.5±5.8	7.8±4.8	0.537
Secondary Infection* (%)	17 (20.2)	9 (17.6)	8 (24.2)	0.462

^{*}Secondary infection includes Ventilator associated pneumonia (VAP) and blood-stream infection (bacteremia).

Table 4- Baseline Characteristics Comparing Living versus Deceased patients:

Demographics	Total	Living	Deceased	P-value
Demographics	n=84	n=68	n=16	1 -value
	11-04	11-08	11–10	
Gender (%)				0.094
Male	53 (63.1)	40 (58.8)	13 (81.3)	
Female	31 (36.9)	28 (41.2)	3 (18.8)	
Mean Age, years	60.6±13.4	57.8±12.7	72.8±8.7	<0.0001
Ethnicity (%)				0.141
AA	45 (53.6)	35 (51.5)	10 (62.5)	
Hispanic	25 (29.8)	22 (32.4)	3 (18.8)	
Caucasian	13 (15.5)	11 (16.2)	2 (12.5)	
Not known /NON	1 (1.2)	0 (0.0)	1 (6.3)	
Hispanic				
Mean BMI	31.4±8	32.6±8.0	26.7±5.7	0.008
(kg/m^2)				
COVID PCR	65 (77.4)	51 (75.0)	14 (87.5)	0.282
positive status				
Therapy given:				0.464
Anakinra/IVIG	51 (60.7)	40 (58.8)	11 (68.8)	
Tocilizumab (%)	33 (39.3)	28 (41.2)	5 (31.3)	
		Comorbidities		
COPD (%)	23 (27.4)	17 (25.0)	6 (37.5)	0.313
Asthma (%)	8 (9.5)	8 (11.8)	0 (0.0)	0.149
HTN (%)	60 (71.4)	46 (67.6)	14 (87.5)	0.114

DM (%)	36 (42.9)	29 (42.6)	7 (43.8)	0.936
CAD (%)	16 (19.0)	8 (11.8)	8 (50.0)	0.0005
CHF (%)	17 (20.2)	11 (16.2)	6 (37.5)	0.056
CKD (%)	12 (14.3)	7 (10.3)	5 (31.3)	0.031
ESRD on dialysis (%)	11 (13.1)	5 (7.4)	6 (37.5)	0.001
Malignancy (%)	4 (4.8)	2 (2.9)	2 (12.5)	0.106
HIV (%)	4 (4.8)	4 (5.9)	0 (0.0)	0.320
Highest Corticosteroid dose (Methylprednisol one) (mg)	229.1±142.1	217.8±140.6	277.2±142.6	0.133

Table 5- Baseline Laboratory, Respiratory Function and Clinical Data in Living versus Deceased Patients

	Total n=84	Living n=68	Deceased n=16	P value		
	Baseline laboratory Inflammatory Markers					
CRP (mg/L)	8.9±7.0	8.4±6.3	10.6±9.2	0.288		
Ferritin (ng/mL)				0.097		
Mean (SD)	1599.2±5084.2	581.0±516.4	5672.2±10664.8			
Median (IQR)	563.5 (247.0-993.0)	468.5 (202.0-	1359.5 (648.0-			
		821.5)	2610.0)			
LDH (U/L)	446.4±463.4	357.9±194.9	794.6±894.1	0.081		
AST (U/L)				0.175		
Mean (SD)	116.8±386.5	55.8±92.4	356.9±816.1			
Median (IQR)	37.5 (25.0-66.0)	35.0 (23.0-48.0)	71.0 (36.0-217.0)			
ALT (U/L)				0.240		
Mean (SD)	97.1±250.5	64.4±107.2	226.0±507.3			
Median (IQR)	43.0 (22.0-69.0)	43.0 (23.0-61.0)	39.0 (17.0-134.0)			
Albumin (g/dL)	2.6±0.4	2.6±0.4	2.4±0.4	0.132		
D-dimer (ng/mL)				0.170		
Mean (SD)	4328.3±14055.6	2065.7±4251.7	13540.1±29531.0			
Median (IQR)	843.0 (521.0-	814.0 (514.0-	1642.5 (830.0-			
	1745.0)	1291.0)	7498.0)			
Fibrinogen (mg/mL)	519.3±163.7	547.7±143.0	421.1±196.1	0.007		
Triglycerides (mg/mL)	141±87.8	139.5±87.1	145.8±93.1	0.810		

Absolute Lymphocyte Count (K/mm³) BUN/Creatinine	0.9±0.6 23.9±12.4	1.0±0.6 23.9±10.0	0.7±0.5 23.8±19.8	0.075
ratio				
	Resp	piratory Function		
Mean ROX day 0	11.6±7.5	12.7±7.4	6.6±6.3	0.003
Maximum Oxygen Therapy				<0.0001
None (%)	6 (7.1)	5 (7.4)	1 (6.3)	
NC (%)	38 (45.2)	38 (55.9)	0 (0.0)	
HFNT (%)	20 (23.8)	15 (22.1)	5 (31.3)	
NIPPV (%)	3 (3.6)	3 (4.4)	0 (0.0)	
IMV (%)	16 (19.0)	6 (8.8)	10 (62.5)	
ECMO (%)	1 (1.2)	1 (1.5)	0 (0.0)	
Clinical Data				
NEWS score Day 0	6.3±3.6	5.7±3.3	9.2±3.5	0.0003

^{*}NC- Nasal cannula, HFNT- High flow nasal Therapy, NIPPV- Non-invasive Positive Pressure

Ventilation, IMV - invasive mechanical Ventilation, ECMO- Extracorporeal Membrane oxygenation,

NEWS - National early warning Score

Table 6- Clinical Outcomes in Living versus Decreased Patients

Outcome	Total n=84	Living n=68	Deceased n=16	P-value
Intubation (%)	16 (19.0)	6 (8.8)	10 (62.5)	<0.0001
Need for ICU (%)	36 (52.9)	22 (42.3)	14 (87.5)	0.002
Composite outcome (death, intubation, ICU admission) (%)	38 (45.2)	22 (32.4)	16 (100)	<0.0001
Hospital Length of Stay (LOS) (days)	14±10.4	13.8±10.9	14.6±8.1	0.783
ICU LOS (days) Mean Median (IQR)	8.5±7.0 6.5 (3.0-12.0)	8.5±8.3 5.0 (3.0-12.0)	8.4±4.6 8.5 (6.0-12)	0.974
Duration of Invasive Mechanical of Ventilation (days)	13.3±10.9	15.1±10.3	11.8±11.8	0.559
Change in NEWS score from baseline at Day 7	-2.1±3.3	-2.5±3.1	-0.7±3.7	0.050
Change in NEWS score from baseline at day 14	-2.2±3.2	-2.5±2.9	-0.8±4.1	0.274
Change in ROX index from	5.6±6.6	6.7±6.5	0.8±4.5	0.0010

baseline at day 7				
Change in ROX index from baseline at Day 14	7.2±5.3	7.7±5.0	4.7±6.3	0.245
Secondary Infection* (%)	17 (20.2)	10 (14.7)	7 (43.8)	0.009

^{*}Secondary infection includes Ventilator associated pneumonia (VAP) and blood-stream infection (bacteremia).

Figure 1. Survival Probability displaying no difference in survival between patients treated with Anakinra/IVIG vs. Tocilizumab.





Figure 2. Comparison of the mean data of each inflammatory marker concentration over time among patients of the Anakinra/IVIG and Tocilizumab groups. Day 0 corresponds to the date of initiation of therapy. Data are presented for patients who survived and those who died in each treatment group on separate curves for comparison. Displayed within each graph is the p value for the rate of change for each inflammatory marker comparing living and deceased at day 14 post initiation of therapy.



Supplement:

Table-7

P values comparing the rate of change in inflammatory markers at day 14 compared to baseline

Inflammatory Marker	p value comparing living and	p value comparing Anakinra
	deceased at day 14	and Tocilizumab group at day
		14
CRP	0.052	0.995
BUN/Creatinine ratio	0.182	0.193
Albumin	<0.0001	0.468
Fibrinogen	0.051	0.586
Absolute lymphocyte count	0.001	0.299
Relative lymphocyte count	0.006	0.967